Roche scores adjuvant lung cancer approval for Tecentriq

[cafead]

via Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage cases that can be treated with surgery.

article source